Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Canaccord Calls Doximity, Inc. (DOCS)’s Post-Earnings Selloff an Overreaction And Sees Long-Term Upside
Canaccord Calls Doximity, Inc. (DOCS)’s Post-Earnings Selloff an Overreaction And Sees Long-Term Upside
Laiba Immad
Wed, February 18, 2026 at 3:12 PM GMT+9 2 min read
In this article:
DOCS
-1.76%
Doximity, Inc. (NYSE:DOCS) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.
Canaccord Calls Doximity, Inc. (DOCS)'s Post-Earnings Selloff an Overreaction And Sees Long-Term Upside
The stock given seventh position on our list of best healthcare stocks is Doximity, Inc. (NYSE:DOCS).
TheFly reported on February 9 that Canaccord Genuity upgraded DOCS from Hold to Buy and lowered the price target to $34 from $48. The post-earnings selloff, according to the firm, was an overreaction to immediate worries about how policy and pricing uncertainties might impact pharmaceutical budgets. It was wise to draw a line and upgrade the company, according to Canaccord, which also predicted that DOCS shares would rise sharply over the course of the upcoming year as pharmaceutical budgets level off, offering a longer-term buying opportunity.
Moreover, Doximity, Inc. (NYSE:DOCS) announced its fiscal Q3 2026 results on February 5. The company’s revenue for the quarter ending December 31, 2025, was $185.1 million, a 10% rise over the previous year. While net income reached $61.6 million, suggesting a 33% margin, adjusted EBITDA climbed 9% to $111.4 million, with margins staying at 60%. According to the company, platform engagement reached all-time highs, with 720,000 active users for workflow solutions and over 300,000 people using AI features. CEO Jeff Tangney claims that platform utility has increased as a result of AI integration.
In addition, the company authorized a $500 million stock repurchase program, which underscores confidence in long-term value creation. DOCS also provided guidance for Q4 and full fiscal 2026, projecting revenues of approximately $643 million and adjusted EBITDA near $356 million.
Doximity, Inc. (NYSE:DOCS) is a U.S. digital healthcare platform connecting medical professionals with secure networking, telehealth, AI‑powered workflow tools, and clinical insights. It innovates by embedding AI, telemedicine, and productivity tools into a unified physician‑centric ecosystem that streamlines care delivery, communication, and administrative tasks.
While we acknowledge the potential of DOCS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.
Disclosure: None.
Terms and Privacy Policy
Privacy Dashboard
More Info